TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response
NASH Summit
oral
Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH
NASH and Fibrosis Conference
TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma
European Society for Medical Oncology (ESMO) Congress
Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients
Precison: Lung Cancer R&D Summit
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
International Congress on Targeted Anticancer Therapies
